GlobeNewswire Inc.··Nxera PharmaNxera Pharma Out-Licenses GPCR Program, Eyes $275M in Milestone Payments
Nxera Pharma out-licenses GPCR drug program to new company in Series A funding, retaining $275M milestone potential and Asia-Pacific rights.
LLYdrug discoveryroyalties